European Leukemia Trial Registry
Trial: AIDA2009

less detail
Scientific Title Recommendations for risk adapted treatment of acute promyelocytic leukemia in the AML-SAL-Study group - an observational study -
Short Title AIDA2009
Id KN/ELN LN_SAL_2010_370
Trialgroup SAL
Type of Trial multicentric
Disease Acute myeloid leukemia(AML) FAB M3 (APL)
Stage of Disease de novo/non-treated
Aim
  • registration of number and basic characteristics of patients, remission rates, toxicity and survival
  • long term remission, tolerance
Inclusion Criteria
  • Diagnosis of acute promyelocytic leukemia, based on morphological result and confirmatory cytogenetic/molecular finding of t(15;17) and/or PML/RARΑ
  • no contraindication for chemotherapy
  • informed consent
Exclusion Criteria
  • contraindications for intensive chemotherapy, e.g. cardial co-morbidities
Age >= 18 years
Status Closed
Start of Recruitment 19.10.2009
Recruiting Countries Germany
Scientific Contact Platzbecker, Prof. Dr. med., Uwe (Affliliation)
Contact Person

principal investigator
Platzbecker, Prof. Dr. med., Uwe
Tel: +49 (0)351 4582583
Fax: +49 (0)351 458-5362
Email: Uwe.Platzbecker@uniklinikum-dresden.de

Study Centre
Peschel, Katrin
Tel: +49 (0)351 458 5222
Email: katrin.peschel@uniklinikum-dresden.de

Shortprotocol Shortprotocol
Outcomes
  • CR-Rate, Remissionsdauer, Überleben CR rates, duration of remission, survival (Primary Outcome)
  • Toxizität toxicity
Remark ATRA and chemotherapy followed by Maintenance therapy with chemotherapy and ATRA; www.sal-aml.org
created 15.06.2010 Johannes Kraus
changed 28.08.2014 Johannes Kraus
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org